The year after my periods stopped, I had three chest infections in twelve months. I'd barely had one a decade before. Nobody connected it to menopause — not even me, until I fell down a very long research rabbit hole. The immune system shift is one of the least-talked-about parts of this transition, and it deserves a much bigger conversation.
Learn more about Rose →Estrogen isn't just a reproductive hormone — it actively modulates immune function by binding to receptors on T cells, B cells, and natural killer cells. When estrogen levels fall at menopause, this regulatory signal disappears, and immune responses can become both less targeted and harder to switch off. The result is a system that's simultaneously less agile at fighting specific pathogens and more prone to firing inappropriately against the body's own tissues.
Researchers use the term 'inflammaging' to describe the slow, persistent rise in inflammatory markers like IL-6, TNF-alpha, and CRP that accumulates with age — and menopause significantly accelerates this process. Studies consistently show that postmenopausal women have measurably higher circulating inflammatory cytokines than premenopausal women of similar age, independent of body weight or lifestyle. This background hum of inflammation is now understood to underpin cardiovascular disease, metabolic dysfunction, cognitive changes, and joint pain all at once.
Estrogen maintains the thickness and glycogen content of the urogenital mucosal lining, which in turn supports the lactobacillus-dominant microbiome that keeps opportunistic bacteria in check. After menopause, this lining thins — a condition now called genitourinary syndrome of menopause (GSM) — and the local immune defenses that depended on it weaken considerably. This is why recurrent urinary tract infections become significantly more common after menopause, affecting roughly 10–15% of postmenopausal women regularly.
Natural killer (NK) cells are the immune system's rapid-response patrol — they destroy virus-infected cells and early cancer cells without needing prior exposure to a specific pathogen. Estrogen supports NK cell activity, and its decline at menopause is associated with reduced NK cell cytotoxicity in multiple studies. This partly explains why postmenopausal women tend to experience more severe and longer-lasting viral infections, including respiratory illnesses, compared to premenopausal women.
The immune system's ability to mount a strong antibody response after vaccination — called immunogenicity — depends in part on intact hormonal signaling and a healthy population of naive T and B cells, both of which decline at menopause. Research on influenza vaccines has found that postmenopausal women produce lower antibody titers than premenopausal women receiving the same vaccine, suggesting protection may be less complete. This is one practical reason why staying current with recommended vaccinations matters more, not less, after the menopause transition.
The prevalence of autoimmune conditions including rheumatoid arthritis, Sjögren's syndrome, lupus flares, and Hashimoto's thyroiditis shows a notable clustering around the menopause transition in women. Estrogen normally helps suppress autoreactive immune cells; without it, immune self-tolerance can break down and the body begins attacking its own tissues. Women who already have an autoimmune diagnosis often report a marked worsening of symptoms in perimenopause, which can easily be mistaken for an unrelated disease progression.
Estrogen influences the composition of the gut microbiome through estrobolome — the collection of gut bacteria responsible for metabolizing estrogen — and when estrogen falls, microbial diversity tends to decline in parallel. A less diverse gut microbiome is directly linked to increased intestinal permeability ('leaky gut') and heightened systemic immune activation, creating a feedback loop that amplifies inflammaging. This gut-immune connection helps explain why digestive symptoms, food sensitivities, and systemic inflammation so often appear together after menopause.
The immune system carries out critical repair and regulatory work during deep sleep — producing cytokines, consolidating immunological memory, and clearing cellular debris — and menopause-related sleep disruption directly interferes with all of this. Studies show that even partial sleep deprivation reduces NK cell activity, impairs T cell function, and raises inflammatory markers the following day, creating a compounding effect on top of the hormonal changes already underway. Poor sleep at menopause is not just an inconvenience; it is an active immune stressor.
A growing body of evidence suggests that menopausal hormone therapy (MHT), when started early in the transition, can blunt some of the immune dysregulation associated with estrogen loss — reducing circulating inflammatory markers, supporting mucosal integrity, and improving NK cell function in some studies. The immune benefits are considered a secondary finding rather than the primary indication for MHT, but they add meaningful context to the risk-benefit conversation women have with their clinicians. Local vaginal estrogen in particular has strong evidence for restoring the urogenital mucosal defenses that protect against recurrent UTIs, with minimal systemic absorption.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.